ライフサイエンスコーパス: experimental therapy

1 odds ratio >1 favoring the groups receiving experimental therapy).

2 390 participants who had been randomized to experimental therapy.

3 ons according to authors' endorsement of the experimental therapy.

4 C, although there was no sign of bias toward experimental therapy.

5 y in five fractions to further evaluate this experimental therapy.

6 ond which it makes sense to give the patient experimental therapy.

7 common control arm while evaluating multiple experimental therapies.

8 is provides a guide for future assessment of experimental therapies.

9 resulted in full recovery without the use of experimental therapies.

10 s of MN and evaluating the efficacy of novel experimental therapies.

11 with mutations should be selected for novel experimental therapies.

12 udies of patients, often in conjunction with experimental therapies.

13 ocesses, and new opportunities for exploring experimental therapies.

14 with advanced disease may be candidates for experimental therapies.

15 control of JAB1 could be a novel target for experimental therapies.

16 mechanisms, and in assessing the effects of experimental therapies.

17 tional section of this review will deal with experimental therapies.

18 atment response in animal models of PD after experimental therapies.

19 to define the disease course and response to experimental therapies.

20 for pharmacological TRPC6 modulation within experimental therapies.

21 mulations of hypothetical multiarm trials of experimental therapies and associated biomarkers of vary

22 that can be tailored for rapid assessment of experimental therapies and delivery of precision medicin

23 latforms offer the ability to validate human experimental therapies and may foster their rapid transl

24 erbs may confound the results of standard or experimental therapies and may produce clinically signif

25 identifying epidemiological risk factors and experimental therapies and vaccines.

26 e high expectations regarding the success of experimental therapy and discount potential toxicity.

27 L may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice.

28 ct therapy appropriately toward cure, use of experimental therapies, and/or palliation.

29 re used widely to investigate tumor biology, experimental therapy, and biomarkers.

30 atment is currently symptomatic, but several experimental therapies are in development.

31 een relatively refractory to virtually every experimental therapy attempted.

32 for unruptured brain AVMs may be considered experimental therapy awaiting the results from 'A Random

33 nical trials where patients are matched with experimental therapies based on their genomic profile ra

34 ial for toxicity (29.8% v 45.6%, P =.01) for experimental therapy, compared with standard therapy.

35 long-term effectiveness and side effects of experimental therapies delivered to adult mice, we devel

36 Experimental therapies for Alzheimer's disease (AD) are

37 promise for minimally invasive assessment of experimental therapies for DMD and other neuromuscular d

38 that can be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (

39 With the emergence of experimental therapies for Duchenne muscular dystrophy (

40 hysiological assays in early-phase trials of experimental therapies for PD and other neurodegenerativ

41 his study reviews the newest developments on experimental therapies for the treatment of food allergy

42 ouse model should prove valuable for testing experimental therapies for this devastating disorder and

43 ld be considered in designing and monitoring experimental therapies for this disease.

44 e pathogenesis of BPD as well as current and experimental therapies for treatment of BPD.

45 Recently, IL-12 has been used as an experimental therapy for cancer.

46 Intrahepatic islet transplantation is an experimental therapy for type 1 diabetes.

47 Hence, it is a promising, albeit experimental, therapy for Parkinson's disease (PD).

48 therapy compared with 28% (11 of 39) in the experimental therapy group (p = 0.0001).

49 p but in 0% (0 of 25) of the patients in the experimental therapy group (p = 0.0001).

50 o significantly better among patients in the experimental-therapy group (72+/-3.4 percent vs. 61+/-3.

51 -free survival among the 198 patients in the experimental-therapy group was 69+/-3 percent, as compar

52 to the standard-therapy group and 58 to the experimental-therapy group.

53 While many experimental therapies have shown great promise in treat

54 potential benefits of surgical procedures or experimental therapy have to be weighed against the chan

55 onse to transfusion, and the optimization of experimental therapies in development.

56 ical function, and offer a model for testing experimental therapies in this and similar disorders.

57 ing quantitative measures of the efficacy of experimental therapies in this rodent model of Parkinson

58 n or function may provide a novel target for experimental therapy in patients with ALCL.

59 In addition, a wide range of experimental therapies is routinely provided in an attem

60 mated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8% v 23.

61 otential of repurposing of this drug for the experimental therapy of diabetic cardiovascular complica

62 Experimental therapy of mice bearing peritoneal MKN-45P

63 chanism-based neuromodulating devices in the experimental therapy of RA and possibly other autoimmune

64 rs have entered clinical development for the experimental therapy of various cardiovascular and other

65 5 pathway offers novel opportunities for the experimental therapy of various forms of shock, sepsis,

66 or discrimination of the relative effects of experimental therapies on new inflammatory activity from

67 956-2016) were identified for which the new, experimental therapy provided a statistically significan

68 patient perception of potential benefit from experimental therapy (r =.48, P =.01).

69 rant cell-signaling pathways, as well as new experimental therapies such as immunotherapy.

70 We critically assess the potential of experimental therapies targeting alpha-synuclein, and di

71 Experimental therapies targeting Bcl-2 family mRNAs or p

72 Experimental therapies targeting Bcl-2-family mRNAs or p

73 Several experimental therapies targeting T-cells are in clinical

74 Experimental therapies that are undergoing evaluation in

75 ctors could "prime" the neuron to respond to experimental therapies that promote axonal plasticity or

76 gh-risk disease who should be considered for experimental therapy that might improve outcome.

77 patients into two groups, one to receive the experimental therapy, the other serving as the control.

78 h immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antib

79 re directed towards the development of novel experimental therapies to target these molecular and bio

80 d therapy was weekly cisplatin 40 mg/m2, and experimental therapy was PVI FU 225 mg/m2/d for 5 d/wk f

81 r to improve the safety and efficacy of this experimental therapy, we need a better understanding of

82 These and other experimental therapies will be discussed critically.

83 We tested the antitumor activity of experimental therapy with 2 distinct antiangiogenic drug

84 Ribavirin is used as an experimental therapy with other viruses.

85 The patient received experimental therapy with quinacrine, but deteriorated a

86 to demonstrate the feasibility of monitoring experimental therapy with siRNA in vivo, targeted knockd

87 stine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating w

88 atment outcomes (eg, median 60% benefit from experimental therapy), with those choosing to participat